JAM3 maintains leukemia-initiating cell self-renewal through LRP5/AKT/β-catenin/CCND1 signaling
Yaping Zhang, … , Guo-Qiang Chen, Junke Zheng
Yaping Zhang, … , Guo-Qiang Chen, Junke Zheng
Published March 26, 2018
Citation Information: J Clin Invest. 2018;128(5):1737-1751. https://doi.org/10.1172/JCI93198.
View: Text | PDF
Research Article Hematology Stem cells

JAM3 maintains leukemia-initiating cell self-renewal through LRP5/AKT/β-catenin/CCND1 signaling

Abstract

Leukemia-initiating cells (LICs) are responsible for the initiation, development, and relapse of leukemia. The identification of novel therapeutic LIC targets is critical to curing leukemia. In this report, we reveal that junctional adhesion molecule 3 (JAM3) is highly enriched in both mouse and human LICs. Leukemogenesis is almost completely abrogated upon Jam3 deletion during serial transplantations in an MLL-AF9–induced murine acute myeloid leukemia model. In contrast, Jam3 deletion does not affect the functions of mouse hematopoietic stem cells. Moreover, knockdown of JAM3 leads to a dramatic decrease in the proliferation of both human leukemia cell lines and primary LICs. JAM3 directly associates with LRP5 to activate the downstream PDK1/AKT pathway, followed by the downregulation of GSK3β and activation of β-catenin/CCND1 signaling, to maintain the self-renewal ability and cell cycle entry of LICs. Thus, JAM3 may serve as a functional LIC marker and play an important role in the maintenance of LIC stemness through unexpected LRP5/PDK1/AKT/GSK3β/β-catenin/CCND1 signaling pathways but not via its canonical role in cell junctions and migration. JAM3 may be an ideal therapeutic target for the eradication of LICs without influencing normal hematopoiesis.

Authors

Yaping Zhang, Fangzhen Xia, Xiaoye Liu, Zhuo Yu, Li Xie, Ligen Liu, Chiqi Chen, Haishan Jiang, Xiaoxin Hao, Xiaoxiao He, Feifei Zhang, Hao Gu, Jun Zhu, Haitao Bai, Cheng Cheng Zhang, Guo-Qiang Chen, Junke Zheng

×

Figure 7

JAM3 supports the growth of human acute myeloid LICs.

Options: View larger image (or click on image) Download as PowerPoint
JAM3 supports the growth of human acute myeloid LICs. (A) Representative...
(A) Representative flow cytometric analysis of JAM3 expression on the immunophenotypic Lin–CD34+CD38–CD90–CD45RA+ LICs (LMPP cells) and CD34–CD38– differentiated human AML cells (AML#7 in Supplemental Table 2). (B) Quantification of the MFIs for JAM3 expression on LMPP cells or CD34–CD38– differentiated leukemia cells in A (AML#2, #5, #6, #8 in Supplemental Table 2; n = 5; *P < 0.05, Student’s t test). (C) Quantification of the relative frequency of JAM3+ cells in LMPP or CD34–CD38– differentiated leukemia cells in A (n = 5; *P < 0.05, Student’s t test). (D–H) Cell numbers of 5 patient AML samples were counted at the indicated days after knockdown of JAM3 by sh1188 or scrambled shRNA (AML#1–AML#5 in Supplemental Table 2; n = 3; **P < 0.01, ***P < 0.001, 2-way ANOVA followed by Bonferroni’s post-test). Experiments were conducted 3–5 times for validation.